Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Christine E Hallgreen"'
Publikováno v:
PLoS ONE, Vol 17, Iss 4, p e0266353 (2022)
Pediatric legislations in the European Union (EU) and the United States (US) have increased medicines approved for use in the pediatric population. Despite many similarities between these frameworks, the EU Paediatric Regulation more often provides r
Externí odkaz:
https://doaj.org/article/92fac2e94a324bc381bf628194448c73
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Mandatory pediatric legislation has been implemented in the European Union (EU) and the United States (US) to increase research and the availability of drugs for the pediatric population. Differences in the legislative framework can cause different p
Externí odkaz:
https://doaj.org/article/76ced31c8dcb40fbbbeb8b58b790bd4c
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
The need to optimize drug development and facilitate faster access for patients has ignited discussions around the importance of improving interactions between health technology assessment (HTA) bodies and regulatory agencies. In this study, we condu
Externí odkaz:
https://doaj.org/article/7babf9c46e814066a668254caacbc14b
Autor:
Richard Ofori-Asenso, Christine E. Hallgreen, Marie Louise De Bruin, Per Sindahl, Helga Gardarsdottir, Kaare Kemp
Publikováno v:
British Journal of Clinical Pharmacology, 88(3), 1379. NLM (Medline)
Sindahl, P, Ofori-Asenso, R, Hallgreen, C E, Kemp, K, Gardarsdottir, H & Bruin, M L D 2022, ' Impact of regulatory interventions to restrict the combined use of renin-angiotensin system-acting agents: A Danish nationwide drug utilisation study ', British Journal of Clinical Pharmacology, vol. 88, no. 3, pp. 1379-1384 . https://doi.org/10.1111/bcp.15080
Sindahl, P, Ofori-Asenso, R, Hallgreen, C E, Kemp, K, Gardarsdottir, H & Bruin, M L D 2022, ' Impact of regulatory interventions to restrict the combined use of renin-angiotensin system-acting agents: A Danish nationwide drug utilisation study ', British Journal of Clinical Pharmacology, vol. 88, no. 3, pp. 1379-1384 . https://doi.org/10.1111/bcp.15080
This study aimed to evaluate the impact of the risk minimisation measures issued by the European Medicines Agency in 2014 to restrict the combined use of renin-angiotensin system (RAS) agents in Denmark. Data from the Danish National Prescription Reg
Autor:
Nancy A Dreyer, Stella Blackburn, Christine E. Hallgreen, Shahrul Mt-Isa, Maja Laursen, Alison Bourke
Publikováno v:
Pharmacoepidemiology and Drug Safety. 29:328-336
Publikováno v:
Frontiers in Medicine
Frontiers in Medicine, Vol 7 (2020)
Ofori-Asenso, R, Hallgreen, C E & De Bruin, M L 2020, ' Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies : A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges ', Frontiers in Medicine, vol. 7, 582634 . https://doi.org/10.3389/fmed.2020.582634
Frontiers in Medicine, 7. Frontiers Media S.A.
Frontiers in Medicine, Vol 7 (2020)
Ofori-Asenso, R, Hallgreen, C E & De Bruin, M L 2020, ' Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies : A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges ', Frontiers in Medicine, vol. 7, 582634 . https://doi.org/10.3389/fmed.2020.582634
Frontiers in Medicine, 7. Frontiers Media S.A.
The need to optimize drug development and facilitate faster access for patients has ignited discussions around the importance of improving interactions between health technology assessment (HTA) bodies and regulatory agencies. In this study, we condu
Autor:
Lisa Bero, Gavin Wk Wong, Christine E. Hallgreen, Joel Lexchin, Lorri Puil, Dee Mangin, Barbara Mintzes
Publikováno v:
Cochrane Database Syst Rev
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The main objective is to assess the impact of post‐market regulatory safety advisories on safety outcomes in patients. Other objectives are to assess the impact
Publikováno v:
Therapeutic innovationregulatory science. 54(3)
Background: Despite increasing interest and focus on patient-centric approaches to drug development, there might still be divergent views between key stakeholders in how to perceive patient involvement and how possibly divergent views influence the r
Autor:
Gerald Downey, Ed Waddingham, Lawrence D. Phillips, Alfons Lieftucht, Kimberley Hockley, Alain Micaleff, Rebecca Noel, Deborah Ashby, Diana Hughes, Christine E. Hallgreen, Shahrul Mt-Isa, Edmond Chan, Juhaeri Juhaeri, Marilyn Metcalf, Alesia Goginsky
Publikováno v:
Pharmacoepidemiology and Drug Safety. 25:251-262
Purpose The purpose of this study is to draw on the practical experience from the PROTECT BR case studies and make recommendations regarding the application of a number of methodologies and visual representations for benefit–risk assessment. Method
Autor:
Alex Asiimwe, Alfons Lieftucht, Georgy Genov, Deborah Ashby, Ioanna Tzoulaki, Alain Micaleff, Rebecca Noel, Richard C. Hermann, Ruth Peters, Christine E. Hallgreen, Shahrul Mt-Isa, Gerald Downey, Lawrence D. Phillips, Susan Talbot, Diana Hughes
Publikováno v:
Pharmacoepidemiology and Drug Safety. 25:238-250
Background The PROTECT Benefit–Risk group is dedicated to research in methods for continuous benefit–risk monitoring of medicines, including the presentation of the results, with a particular emphasis on graphical methods. Methods A comprehensive